메뉴 건너뛰기
Clinical Oncology
Volumn 18, Issue 7, 2006, Pages 511-512
Targeting Renal Cell Carcinoma
Author keywords

[No Author keywords available]
Indexed keywords

AZ 2171; BEVACIZUMAB; FLUOROURACIL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; PTK 767; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;
EID: 33746410155     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.06.006     Document Type: Editorial
Times cited : (1)
References (8)
  • 1
    • 21644487878 scopus 로고    scopus 로고
    • The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress
    • Larkin J.M., and Gore M.E. The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress. Clin Oncol (R Coll Radiol) 17 (2005) 319-321
    • (2005) Clin Oncol (R Coll Radiol) , vol.17 , pp. 319-321
    • Larkin, J.M.1    Gore, M.E.2
  • 2
    • 23244458246 scopus 로고    scopus 로고
    • Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development
    • Rini B.I., Sosman J.A., and Motzer R.J. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96 (2005) 286-290
    • (2005) BJU Int , vol.96 , pp. 286-290
    • Rini, B.I.1    Sosman, J.A.2    Motzer, R.J.3
  • 3
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 4
    • 19744365702 scopus 로고    scopus 로고
    • A small molecule-kinase interaction map for clinical kinase inhibitors
    • Fabian M.A., Biggs III W.H., Treiber D.K., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23 (2005) 329-336
    • (2005) Nat Biotechnol , vol.23 , pp. 329-336
    • Fabian, M.A.1    Biggs III, W.H.2    Treiber, D.K.3
  • 5
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3
  • 6
    • 23844455555 scopus 로고    scopus 로고
    • Final findings from a phase II, placebo controlled, randomised discontinuation trail of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma
    • Ratain M., Eisen T., Stadler W., et al. Final findings from a phase II, placebo controlled, randomised discontinuation trail of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol (2005) 23
    • (2005) J Clin Oncol , pp. 23
    • Ratain, M.1    Eisen, T.2    Stadler, W.3
  • 7
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
    • (2006) J Clin Oncol , vol.24 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3
  • 8
    • 1442290393 scopus 로고    scopus 로고
    • Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
    • Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
    • (2004) J Clin Oncol , vol.22 , pp. 454-463
    • Motzer, R.J.1    Bacik, J.2    Schwartz, L.H.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.